Clinical trial
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2…
NCT00216073 · Hoosier Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00216073 |
|---|---|
| Title | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer |
| Official title | A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients With HER-2 Positive Metastatic Breast Cancer: Hoosier Oncology Group BRE03-61 |
| Lead sponsor | Hoosier Cancer Research Network, Other |
| Collaborators | Sanofi Industry Hoffmann-La Roche Walther Cancer Institute |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Oxaliplatin, Trastuzumab |
| Enrollment | 11 |
| Start date | Mar 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | May 2, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: